Related Experiment Video

Updated: Jun 20, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss

Feng-Sheng Wang1, Jih-Yang Ko, Lin-Hsiu Weng

  • 1Department of Medical Research, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan. wangfs@ms33.hinet.net

Life Sciences
|September 29, 2009
PubMed
Abstract

Insights

Inhibiting glycogen synthase kinase-3beta (GSK-3beta) prevents bone loss caused by glucocorticoids. This approach enhances osteoblast differentiation and bone mass, offering a potential treatment for glucocorticoid-induced osteopenia.

Area of Science:

  • Bone Biology and Pharmacology
  • Endocrinology and Metabolism

Background:

  • Long-term glucocorticoid use is a significant cause of bone deterioration and osteopenia.
  • Glycogen synthase kinase-3beta (GSK-3beta) signaling plays a crucial role in bone remodeling processes.

Purpose of the Study:

  • To investigate the potential of GSK-3beta inhibitors in counteracting glucocorticoid-induced bone loss.
  • To determine if GSK-3beta inhibition can restore osteoblast differentiation and bone mass affected by glucocorticoids.

Main Methods:

  • MC3T3-E1 osteoblasts and rat bone tissues were treated with GSK-3beta inhibitors (kinase-inactive mutant, BIO) and dexamethasone or methylprednisolone.
  • Osteoblast differentiation, apoptosis, and cell survival were assessed using molecular and staining techniques.
  • Bone mineral density, biomechanical properties, and microarchitecture were analyzed via dual-energy X-ray absorptiometry, material testing, and histomorphometry.

Main Results:

  • Glucocorticoids reduced phosphorylated Ser9-GSK-3beta and beta-catenin levels, promoting apoptosis and inhibiting osteoblast differentiation.
  • GSK-3beta inhibition (using mutant or BIO) preserved beta-catenin and Runx2 levels, enhanced osteoblast differentiation, and reduced apoptosis.
  • BIO treatment improved bone mineral density, biomechanical strength, and bone formation while decreasing osteoclast surface and marrow adiposity in glucocorticoid-treated rats.

Conclusions:

  • Inhibition of GSK-3beta effectively abrogates glucocorticoid-induced bone loss.
  • This protective effect is mediated by enhanced beta-catenin and Runx2 signaling, promoting osteoblast differentiation.
  • Targeting GSK-3beta signaling presents a promising therapeutic strategy for preventing glucocorticoid-induced osteopenia.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...